BioXcel Therapeutics, Inc. (BTAI)
NASDAQ · Healthcare
BioXcel Therapeutics, Inc. Shareholder Equity 2022–2025
BioXcel Therapeutics, Inc. annual/quarterly shareholder equity history from 2022 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- BioXcel Therapeutics, Inc. shareholder equity for the quarter ending December 31, 2025 were -95.5M, a 2.54% increase year-over-year.
- BioXcel Therapeutics, Inc. shareholder equity for 2025 were -95.5M, a 2.54% increase from 2024.
- BioXcel Therapeutics, Inc. shareholder equity for 2024 were -93.1M, a 64.76% increase from 2023.
- BioXcel Therapeutics, Inc. shareholder equity for 2023 were -56.5M, a 173.60% decrease from 2022.
- BioXcel Therapeutics, Inc. shareholder equity for 2022 were 76.8M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| BioXcel Therapeutics, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $-95 |
| 2024 | $-93 |
| 2023 | $-57 |
| 2022 | $77 |
| BioXcel Therapeutics, Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $-95 |
| 2024-12-31 | $-93 |
| 2023-12-31 | $-57 |
| 2022-12-31 | $77 |
BioXcel Therapeutics, Inc. Shareholder Equity — FAQ
BioXcel Therapeutics, Inc. (BTAI) shareholder equity over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BTAI's shareholder equity history?
The chart and table above show BioXcel Therapeutics, Inc.'s shareholder equity by year and by quarter, including the growth rate.